New hopes for curing cancerExpress.co.ukCancer Research UK-funded scientists at Southampton and Manchester universities have played an important part in another breakthrough which has been used to supercharge the antibody drug MabThera (drug name ritux…
FDA asks Teva for more Treanda dataGlobesThe company added that Treanda remains available and is a safe and an effective treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment…
|
Cell Therapeutics’ Pixuvri receives marketing approval from Italian Medicines …
pharmabiz.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have … |
CD30 expression in EBV+ DLBCL confers poor prognosisThe Oncology ReportAll were uniformly treated with rituximab plus chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), said Dr. Young of the department of hematopatho…
|
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma …
The Herald | HeraldOnline.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
Market Access Granted In Italy For Aggressive Non-Hodgkin Lymphoma …Daily Markets (press release)CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cel…
Rituximab plus chlorambucil extend event-free survival in MALT lymphomaThe Oncology ReportPatients who have mucosa-associated lymphoid tissue lymphoma and are treated with chlorambucil plus rituximab have better event-free survival and progression-free…
|
In the fight against cancer, do Quebeckers stand the same chance?
Canada NewsWire (press release) “This decision could have a major impact for Quebec patients, since bendamustine combined with rituximab, is the only new treatment since the introduction of rituximab to have demonstrated a significant clinical improvement for patients living with an … |
Obinutuzumab plus chlorambucil packs 1-2 punch against CLL in elderlyThe Oncology ReportIn the phase III CLL11 study, median progression-free survival (PFS) was 23 months for patients treated with a combination of obinutuzumab (GA101) and chlorambucil …
|
NICE issues second draft guidance on the use of Pixuvri as monotherapy to …
pharmabiz.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have … |